RB Capital Management LLC Acquires Shares of 2,988 TransMedics Group, Inc. $TMDX

Key Points

• RB Capital Management LLC has acquired 2,988 shares of TransMedics Group, Inc. valued at approximately $201,000, as reported in their recent 13F filing.
• Several hedge funds have increased their stakes in TransMedics, with New York State Teachers Retirement System growing their ownership by 183.2%, now holding 21,949 shares valued at $1,477,000.
• Wall Street brokerages have raised their price targets for TransMedics Group, with Canaccord Genuity increasing its price objective from $129.00 to $142.00 and maintaining a "buy" rating.

RB Capital Management LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 2,988 shares of the company's stock, valued at approximately $201,000.

Other hedge funds have also recently bought and sold shares of the company. OneDigital Investment Advisors LLC grew its stake in TransMedics Group by 52.6% during the 1st quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company's stock valued at $403,000 after purchasing an additional 2,065 shares in the last quarter. Principal Financial Group Inc. grew its stake in TransMedics Group by 2.8% during the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company's stock valued at $13,350,000 after purchasing an additional 5,480 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in TransMedics Group during the 1st quarter valued at approximately $291,000. New York State Teachers Retirement System grew its stake in TransMedics Group by 183.2% during the 1st quarter. New York State Teachers Retirement System now owns 21,949 shares of the company's stock valued at $1,477,000 after purchasing an additional 14,200 shares in the last quarter. Finally, Sugar Maple Asset Management LLC acquired a new stake in TransMedics Group during the 1st quarter valued at approximately $740,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Insider Transactions at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the transaction, the insider owned 13,955 shares in the company, valued at $1,950,909. The trade was a 4.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.00% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TMDX. Canaccord Genuity Group raised their price objective on TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Piper Sandler reiterated an "overweight" rating and issued a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Oppenheimer lifted their target price on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Monday. Finally, Morgan Stanley lifted their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, TransMedics Group has a consensus rating of "Moderate Buy" and a consensus target price of $123.00.

TransMedics Group Price Performance

Shares of TMDX opened at $117.38 on Thursday. The firm has a market cap of $4.00 billion, a price-to-earnings ratio of 60.82 and a beta of 2.09. The stock has a 50 day moving average of $120.56 and a 200-day moving average of $102.19. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $176.32.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same quarter in the previous year, the firm posted $0.35 EPS. The business's revenue for the quarter was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. As a group, analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.